Amylyx Pharmaceuticals Etf Net Income
| AMLX Etf | USD 13.98 0.99 7.62% |
As of the 8th of February, Amylyx Pharmaceuticals shows the Risk Adjusted Performance of 0.0324, downside deviation of 3.43, and Mean Deviation of 3.12. Amylyx Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.
Amylyx Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Amylyx Pharmaceuticals' valuation are provided below:Gross Profit -92.7 M | Market Capitalization 1.5 B | Enterprise Value Revenue 6.4 K | Revenue | Earnings Share (1.79) |
The market value of Amylyx Pharmaceuticals is measured differently than its book value, which is the value of Amylyx that is recorded on the company's balance sheet. Investors also form their own opinion of Amylyx Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Amylyx Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amylyx Pharmaceuticals' market value can be influenced by many factors that don't directly affect Amylyx Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Amylyx Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Amylyx Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Amylyx Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Amylyx Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Amylyx Pharmaceuticals' etf what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Amylyx Pharmaceuticals.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Amylyx Pharmaceuticals on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Amylyx Pharmaceuticals or generate 0.0% return on investment in Amylyx Pharmaceuticals over 90 days. Amylyx Pharmaceuticals is related to or competes with SmartRent, ReposiTrak, A2Z Smart, 8x8 Common, Marti Technologies, Forge Global, and ON24. Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for... More
Amylyx Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Amylyx Pharmaceuticals' etf current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Amylyx Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.43 | |||
| Information Ratio | 0.0091 | |||
| Maximum Drawdown | 22.15 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 8.11 |
Amylyx Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amylyx Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Amylyx Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Amylyx Pharmaceuticals historical prices to predict the future Amylyx Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0324 | |||
| Jensen Alpha | 0.1162 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0113 | |||
| Treynor Ratio | 4.13 |
Amylyx Pharmaceuticals February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0324 | |||
| Market Risk Adjusted Performance | 4.14 | |||
| Mean Deviation | 3.12 | |||
| Semi Deviation | 3.36 | |||
| Downside Deviation | 3.43 | |||
| Coefficient Of Variation | 3317.16 | |||
| Standard Deviation | 4.26 | |||
| Variance | 18.17 | |||
| Information Ratio | 0.0091 | |||
| Jensen Alpha | 0.1162 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0113 | |||
| Treynor Ratio | 4.13 | |||
| Maximum Drawdown | 22.15 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 8.11 | |||
| Downside Variance | 11.77 | |||
| Semi Variance | 11.3 | |||
| Expected Short fall | (3.57) | |||
| Skewness | 1.2 | |||
| Kurtosis | 2.35 |
Amylyx Pharmaceuticals Backtested Returns
Amylyx Pharmaceuticals appears to be somewhat reliable, given 3 months investment horizon. Amylyx Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0723, which signifies that the etf had a 0.0723 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Amylyx Pharmaceuticals, which you can use to evaluate the volatility of the entity. Please makes use of Amylyx Pharmaceuticals' Risk Adjusted Performance of 0.0324, mean deviation of 3.12, and Downside Deviation of 3.43 to double-check if our risk estimates are consistent with your expectations. The etf shows a Beta (market volatility) of 0.0287, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Amylyx Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Amylyx Pharmaceuticals is expected to be smaller as well.
Auto-correlation | 0.10 |
Insignificant predictability
Amylyx Pharmaceuticals has insignificant predictability. Overlapping area represents the amount of predictability between Amylyx Pharmaceuticals time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Amylyx Pharmaceuticals price movement. The serial correlation of 0.1 indicates that less than 10.0% of current Amylyx Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.1 | |
| Spearman Rank Test | -0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 2.54 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Amylyx Pharmaceuticals reported net income of (301.74 Million). This is much lower than that of the Pharmaceuticals family and significantly lower than that of the Health Care category. The net income for all United States etfs is notably higher than that of the company.
Amylyx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amylyx Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Amylyx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Amylyx Pharmaceuticals by comparing valuation metrics of similar companies.Amylyx Pharmaceuticals is currently under evaluation in net income as compared to similar ETFs.
Amylyx Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amylyx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Amylyx Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amylyx Pharmaceuticals competition to find correlations between indicators driving Amylyx Pharmaceuticals's intrinsic value. More Info.Amylyx Pharmaceuticals is the top ETF in price to book as compared to similar ETFs. It also is the top ETF in price to sales as compared to similar ETFs fabricating about 0.96 of Price To Sales per Price To Book. The ratio of Price To Book to Price To Sales for Amylyx Pharmaceuticals is roughly 1.04 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amylyx Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Amylyx Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Amylyx Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Amylyx Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amylyx Pharmaceuticals' value.| Shares | Great Point Partners Llc | 2025-06-30 | 2 M | Geode Capital Management, Llc | 2025-06-30 | 1.7 M | Millennium Management Llc | 2025-06-30 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 1.3 M | Driehaus Capital Management Llc | 2025-06-30 | 1.3 M | Ubs Group Ag | 2025-06-30 | 1.3 M | Citadel Advisors Llc | 2025-06-30 | 1.2 M | Boxer Capital Management, Llc | 2025-06-30 | 1.2 M | Adar1 Capital Management Llc | 2025-06-30 | 1.2 M | Adage Capital Partners Gp Llc | 2025-06-30 | 8.8 M | Perceptive Advisors Llc | 2025-06-30 | 7.9 M |
Fund Asset Allocation for Amylyx Pharmaceuticals
The fund invests 50.03% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Amylyx Pharmaceuticals' investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors for a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will manage securities in the fund's portfolio as market conditions and the fund's objectives change.
Amylyx Fundamentals
| Return On Equity | -0.57 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | 291.04 % | ||||
| Current Valuation | 1.2 B | ||||
| Shares Outstanding | 109.82 M | ||||
| Shares Owned By Insiders | 7.55 % | ||||
| Shares Owned By Institutions | 92.44 % | ||||
| Number Of Shares Shorted | 13.44 M | ||||
| Price To Book | 4.62 X | ||||
| Price To Sales | 4.44 X | ||||
| Revenue | 87.37 M | ||||
| Gross Profit | (92.75 M) | ||||
| EBITDA | (290.98 M) | ||||
| Net Income | (301.74 M) | ||||
| Cash And Equivalents | 206.68 M | ||||
| Cash Per Share | 3.53 X | ||||
| Total Debt | 1.98 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.96 X | ||||
| Book Value Per Share | 3.02 X | ||||
| Cash Flow From Operations | (167.65 M) | ||||
| Short Ratio | 7.51 X | ||||
| Earnings Per Share | (1.79) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 20.22 | ||||
| Number Of Employees | 123 | ||||
| Beta | -0.3 | ||||
| Market Capitalization | 1.54 B | ||||
| Total Asset | 193.63 M | ||||
| Retained Earnings | (606.69 M) | ||||
| Working Capital | 161.03 M | ||||
| Net Asset | 193.63 M | ||||
| Equity Positions Weight | 50.03 % |
About Amylyx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amylyx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amylyx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amylyx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.